145 related articles for article (PubMed ID: 36454283)
21. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
[TBL] [Abstract][Full Text] [Related]
22. Treatment of NRAS-mutant melanoma.
Johnson DB; Puzanov I
Curr Treat Options Oncol; 2015 Apr; 16(4):15. PubMed ID: 25796376
[TBL] [Abstract][Full Text] [Related]
23. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
[TBL] [Abstract][Full Text] [Related]
24. Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.
Yan J; Wu X; Yu J; Yu H; Xu T; Brown KM; Bai X; Dai J; Ma M; Tang H; Si L; Chi Z; Sheng X; Cui C; Kong Y; Guo J
Eur J Cancer; 2018 Jan; 89():90-101. PubMed ID: 29245078
[TBL] [Abstract][Full Text] [Related]
25. Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Mangana J; Cheng PF; Schindler K; Weide B; Held U; Frauchiger AL; Romano E; Kähler KC; Rozati S; Rechsteiner M; Moch H; Michielin O; Garbe C; Hauschild A; Hoeller C; Dummer R; Goldinger SM
PLoS One; 2015; 10(10):e0139438. PubMed ID: 26426340
[TBL] [Abstract][Full Text] [Related]
26. MEK inhibitors for the treatment of NRAS mutant melanoma.
Sarkisian S; Davar D
Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
[TBL] [Abstract][Full Text] [Related]
27. NRAS mutations in primary and metastatic melanomas of Japanese patients.
Uhara H; Ashida A; Koga H; Ogawa E; Uchiyama A; Uchiyama R; Hayashi K; Kiniwa Y; Okuyama R
Int J Clin Oncol; 2014; 19(3):544-8. PubMed ID: 23739925
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study.
Si L; Zhang X; Shu Y; Pan H; Wu D; Liu J; Mao L; Wang X; Wen X; Gu Y; Zhu L; Lan S; Cai X; Diede SJ; Dai H; Niu C; Li J; Guo J
Front Immunol; 2022; 13():882471. PubMed ID: 36304457
[TBL] [Abstract][Full Text] [Related]
29. Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma.
Birkeland E; Busch C; Berge EO; Geisler J; Jönsson G; Lillehaug JR; Knappskog S; Lønning PE
Clin Exp Metastasis; 2013 Oct; 30(7):867-76. PubMed ID: 23673558
[TBL] [Abstract][Full Text] [Related]
30. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
31. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
[TBL] [Abstract][Full Text] [Related]
32. Prognostic role of NRAS isoforms in Chinese melanoma patients.
Yan J; Xu L; Yu J; Wu X; Dai J; Xu T; Yu H; Guo J; Kong Y
Melanoma Res; 2019 Jun; 29(3):263-269. PubMed ID: 30489482
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
34. A review of binimetinib for the treatment of mutant cutaneous melanoma.
Koelblinger P; Dornbierer J; Dummer R
Future Oncol; 2017 Aug; 13(20):1755-1766. PubMed ID: 28587477
[TBL] [Abstract][Full Text] [Related]
35. NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.
Li H; Zhang Q; Duan Q; Tan Y; Sun T; Qi C
Front Immunol; 2022; 13():894110. PubMed ID: 35967450
[TBL] [Abstract][Full Text] [Related]
36. Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.
Krisp C; Parker R; Pascovici D; Hayward NK; Wilmott JS; Thompson JF; Mann GJ; Long GV; Scolyer RA; Molloy MP
Br J Cancer; 2018 Sep; 119(6):713-723. PubMed ID: 30116025
[TBL] [Abstract][Full Text] [Related]
37. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
Min KW; Choe JY; Kwon MJ; Lee HK; Kang HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Kim YJ; Kim NY; Kim HY
Pathol Res Pract; 2019 Dec; 215(12):152671. PubMed ID: 31630873
[TBL] [Abstract][Full Text] [Related]
38. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.
Vu HL; Aplin AE
Mol Cancer Res; 2014 Oct; 12(10):1509-19. PubMed ID: 24962318
[TBL] [Abstract][Full Text] [Related]
39. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma.
Tang B; Mo J; Yan X; Duan R; Chi Z; Cui C; Si L; Kong Y; Mao L; Li S; Zhou L; Lian B; Wang X; Bai X; Xu H; Li C; Dai J; Guo J; Sheng X
Eur J Cancer; 2021 Oct; 156():83-92. PubMed ID: 34425407
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
